Clinical Integration Program definition

Clinical Integration Program means the active and ongoing program of clinical quality, efficiency, and cost effectiveness initiatives developed, implemented, and operated by GSQN on behalf of and in collaboration with GSQN Members and GSQN participating physician practices.
Sample 1Sample 2Sample 3
Clinical Integration Program or “CI Program” shall mean the program of Clinical Integration developed, implemented, and operated by CIN on behalf of and in collaboration with CIN’s Participants and Participating Practices.
Sample 1
Clinical Integration Program means a formal, non-exclusive, active and ongoing program of clinical quality initiatives developed, implemented, and operated by CIN in collaboration with Provider in order to create a high degree of coordination and interdependence among Participating Providers with the intent to increase value and efficiency, and improve patient outcomes and includes one or more of the following operating protocols:
Sample 1

Examples of Clinical Integration Program in a sentence

  • Community and Clinical Integration Program (CCIP) found on pages 42-43 of the RFP.

  • For the re-credentialing process, the Credentials Committee will review information received during the prior periods of participation, in accordance with the Peer Review Policy, and information relating to compliance with the Network Participation Agreement and the Clinical Integration Program.

  • Response: Please see Community and Clinical Integration Program (CCIP) under section F.

  • GSQN is a Louisiana limited liability company organized for the purpose of developing and operating the Clinical Integration Program described herein.

  • The Community and Clinical Integration Program (CCIP) states as a goal “introducing new care processes to reduce health equity gaps” (p.

  • The PTTF is responsible for advising on the design of the SIM funded programs that enable care delivery reforms including the Advanced Medical Home (AMH) program and the Community and Clinical Integration Program (CCIP).

  • Community and Clinical Integration Program (CCIP): The Community and Clinical Integration Program builds on AMH by improving care delivery models across ANs participating in PCMH+.

  • Three initiatives for primary care quality improvement are conferred: The Advanced Medical Home (AMH), Community and Clinical Integration Program (CCIP), and Shared Savings Plan.

  • We support this mission through our Clinical Integration Program.

  • Care Delivery Reform initiatives include:  Advanced Medical Home Program (AMH) Community & Clinical Integration Program (CCIP) Community Health Worker initiative (CHW) Prevention Service Initiative (PSI) Advanced Medical Home Goal: Enable primary care practices to become Patient Centered Medical Homes (PCMH) and Advanced Medical Homes (AMH).How it works: Guided technical assistance program including webinars and on-site support to achieve NCQA PCMH and AMH status.

Related to Clinical Integration Program

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Development Program means the implementation of the development plan.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Clinical means having a significant relationship, whether real or potential, direct or indirect, to the actual rendering or outcome of dental care, the practice of dentistry, or the quality of dental care being rendered to a patient;

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Diagnostic source assembly means the tube housing assembly with a beam-limiting device attached.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Program means the executable processing programs of licensed information, which is composed of various modules in the Licensed Software package provided by the Licensor.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Manufacturing Technology means any and all patents, patent applications, know-how, and all intellectual property rights associated therewith that are owned or controlled by Licensor, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno-associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Research Program has the meaning set forth in Section 3.1.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Software Product means any COTS which you propose to provide pursuant to the contract.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Clinical Trial means any human clinical trial of a Product.

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by the JDC and that otherwise fit the foregoing definition.